Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide
Biotech ETFs XBI and IBB each fell about 1.1% by early afternoon in New York, underperforming the broader market. Monte Rosa Therapeutics surged roughly 12% after reporting positive interim Phase 1/2 data for its prostate cancer drug candidate MRT-2359. The company plans a Phase 2 study in 2026. Broader biotech sentiment remained cautious despite sharp moves in select stocks.
